相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Bruton's TK regulates myeloid cell recruitment during acute inflammation
Gareth S. D. Purvis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Brian T. Hopkins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
Ling Li et al.
BIOORGANIC CHEMISTRY (2021)
Orelabrutinib: First Approval
Sohita Dhillon
DRUGS (2021)
The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway
Shengnan Liu et al.
PSYCHOPHARMACOLOGY (2020)
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
Binbin Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
H. Yesid Estupinan et al.
BLOOD ADVANCES (2020)
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Wen-Hao Guo et al.
NATURE COMMUNICATIONS (2020)
STAT3 Activation in Combination with NF-KappaB Inhibition Induces Tolerogenic Dendritic Cells with High Therapeutic Potential to Attenuate Collagen-Induced Arthritis
Carolina Prado et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
Richard D. Caldwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Inhibitor of Breton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages
Zhe Fan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties
Lei Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Inflammasome-Derived Exosomes Activate NF-kappa B Signaling in Macrophages
Yuehui Zhang et al.
JOURNAL OF PROTEOME RESEARCH (2017)
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
T. Seiler et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
NF-kappa B signaling in inflammation
Ting Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus
Susanne Herbst et al.
EMBO MOLECULAR MEDICINE (2015)
Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
Yan Lou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Immune deficiency or hyperactivity-Nf-κb illuminates autoimmunity
Saparna Pai et al.
JOURNAL OF AUTOIMMUNITY (2008)
Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFκB activity
Christine D. Palmer et al.
BLOOD (2008)
Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase
Sarah L. Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide
SL Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Zymosan-induced generalized inflammation: Experimental studies into mechanisms leading to multiple organ dysfunction syndrome
TJH Volman et al.
SHOCK (2005)